Clinical and laboratory evidence of liver injury after gemtuzumab ozogamicin infusion in 11 patients
| Finding . | No. patients with abnormality . | Peak value, median (range) . | Median time (d) from gemtuzumab ozogamicin infusion . |
|---|---|---|---|
| Ascites (onset) | 7 | — | 8 (6-24) |
| Elevated serum AST (normal upper limit < 49 U/L) | 11 | 242 U/L (86-3091) | 8 (3-37) |
| Weight gain from baseline | 7 | 8.9% (5-19.6) | 16 (3-25) |
| Hyperbilirubinemia | 10 | 5.6 mg/dL (1.5-13.2) | 17 (9-41) |
| Elevated serum alkaline phosphatase (normal upper limit < 130 U/L) | 10 | 439 U/L (186-964) | 22 (5-41) |
| Finding . | No. patients with abnormality . | Peak value, median (range) . | Median time (d) from gemtuzumab ozogamicin infusion . |
|---|---|---|---|
| Ascites (onset) | 7 | — | 8 (6-24) |
| Elevated serum AST (normal upper limit < 49 U/L) | 11 | 242 U/L (86-3091) | 8 (3-37) |
| Weight gain from baseline | 7 | 8.9% (5-19.6) | 16 (3-25) |
| Hyperbilirubinemia | 10 | 5.6 mg/dL (1.5-13.2) | 17 (9-41) |
| Elevated serum alkaline phosphatase (normal upper limit < 130 U/L) | 10 | 439 U/L (186-964) | 22 (5-41) |